This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nilius, A. M.
Right arrow Articles by Flamm, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nilius, A. M.
Right arrow Articles by Flamm, R. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2001, p. 2163-2168, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2163-2168.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Comparative In Vitro Activity of ABT-773, a Novel Antibacterial Ketolide

A. M. Nilius,* M. H. Bui, L. Almer, D. Hensey-Rudloff, J. Beyer, Z. Ma, Y. S. Or,dagger and R. K. Flamm

Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537

Received 5 September 2000/Returned for modification 13 February 2001/Accepted 30 March 2001

The in vitro activities of ABT-773, erythromycin, clarithromycin, and azithromycin were compared. ABT-773 was the most active compound against macrolide-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Enterococcus spp. and multidrug-resistant Streptococcus pneumoniae. It also had good activity against gram-negative and atypical respiratory tract pathogens and Helicobacter pylori.


* Corresponding author. Mailing address: D47T, AP52, Abbott Laboratories, Abbott Park, IL 60064-3537. Phone: (847) 937-7706. Fax: (847) 935-0400. E-mail: angela.nilius{at}abbott.com.

dagger Present address: Enanta Pharmaceuticals, Cambridge, MA 02139.


Antimicrobial Agents and Chemotherapy, July 2001, p. 2163-2168, Vol. 45, No. 7
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.7.2163-2168.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Gibreel, A., Taylor, D. E. (2006). Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 58: 243-255 [Abstract] [Full Text]  
  • Mamelli, L., Prouzet-Mauleon, V., Pages, J.-M., Megraud, F., Bolla, J.-M. (2005). Molecular basis of macrolide resistance in Campylobacter: role of efflux pumps and target mutations. J Antimicrob Chemother 56: 491-497 [Abstract] [Full Text]  
  • Rios, A. M., Mejias, A., Chavez-Bueno, S., Fonseca-Aten, M., Katz, K., Hatfield, J., Gomez, A. M., Jafri, H. S., McCracken, G. H. Jr., Ramilo, O., Hardy, R. D. (2004). Impact of Cethromycin (ABT-773) Therapy on Microbiological, Histologic, Immunologic, and Respiratory Indices in a Murine Model of Mycoplasma pneumoniae Lower Respiratory Infection. Antimicrob. Agents Chemother. 48: 2897-2904 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A., McElmeel, M. L., Whitney, C. G. (2004). Activities of Cethromycin and Telithromycin against Recent North American Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 48: 605-607 [Abstract] [Full Text]  
  • Miyashita, N., Fukano, H., Yoshida, K., Niki, Y., Matsushima, T. (2003). In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 52: 497-499 [Abstract] [Full Text]  
  • Morosini, M.-I., Canton, R., Loza, E., del Campo, R., Almaraz, F., Baquero, F. (2003). Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 52: 50-55 [Abstract] [Full Text]  
  • Conejo, M. d. C., Martinez-Martinez, L., Pascual, A., Suarez, A. I., Perea, E. J. (2003). Activities of ABT-773 against Listeria monocytogenes and Coryneform Bacteria of Clinical Interest. Antimicrob. Agents Chemother. 47: 1403-1406 [Abstract] [Full Text]  
  • Dinos, G. P., Connell, S. R., Nierhaus, K. H., Kalpaxis, D. L. (2003). Erythromycin, Roxithromycin, and Clarithromycin: Use of Slow-Binding Kinetics to Compare Their in Vitro Interaction with a Bacterial Ribosomal Complex Active in Peptide Bond Formation. Mol. Pharmacol. 63: 617-623 [Abstract] [Full Text]  
  • Waites, K. B., Crabb, D. M., Duffy, L. B. (2003). In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas. Antimicrob. Agents Chemother. 47: 39-42 [Abstract] [Full Text]  
  • Hamilton-Miller, J. M. T., Shah, S. (2002). Activity of ketolide ABT-773 (cethromycin) against erythromycin-resistant Streptococcus pneumoniae: correlation with extended MLSK phenotypes. J Antimicrob Chemother 50: 907-913 [Abstract] [Full Text]  
  • Weiss, K., Guilbault, C., Cortes, L., Restieri, C., Low, D. E., the EQUERE project (Etude QUEbecoise des pathogene, (2002). Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin. J Antimicrob Chemother 50: 403-406 [Abstract] [Full Text]  
  • Jung, R., Danziger, L. H., Pendland, S. L. (2002). Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila. J Antimicrob Chemother 49: 857-861 [Abstract] [Full Text]  
  • Schmitz, F.-J., Petridou, J., Jagusch, H., Astfalk, N., Scheuring, S., Schwarz, S. (2002). Molecular characterization of ketolide-resistant erm(A)-carrying Staphylococcus aureus isolates selected in vitro by telithromycin, ABT-773, quinupristin and clindamycin. J Antimicrob Chemother 49: 611-617 [Abstract] [Full Text]  
  • Pendland, S. L., Neuhauser, M. M., Prause, J. L. (2002). In vitro bactericidal activity of ABT-773 and amoxicillin against erythromycin-susceptible and -resistant strains of Streptococcus pyogenes. J Antimicrob Chemother 49: 671-674 [Abstract] [Full Text]  
  • Neuhauser, M. M., Prause, J. L., Danziger, L. H., Pendland, S. L. (2001). Postantibiotic Effects of ABT-773 and Amoxicillin-Clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob. Agents Chemother. 45: 3613-3615 [Abstract] [Full Text]  
  • Garza-Ramos, G., Xiong, L., Zhong, P., Mankin, A. (2001). Binding Site of Macrolide Antibiotics on the Ribosome: New Resistance Mutation Identifies a Specific Interaction of Ketolides with rRNA. J. Bacteriol. 183: 6898-6907 [Abstract] [Full Text]  
  • Mitten, M. J., Meulbroek, J., Nukkala, M., Paige, L., Jarvis, K., Oleksijew, A., Tovcimak, A., Hernandez, L., Alder, J. D., Ewing, P., Or, Y. S., Ma, Z., Nilius, A. M., Mollison, K., Flamm, R. K. (2001). Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections. Antimicrob. Agents Chemother. 45: 2585-2593 [Abstract] [Full Text]